jfs2152

VBIV target [$3.50] by July 1st

Long
NASDAQ:VBIV   VBI Vaccines, Inc
Expect a significant appreciation in price leading up to the upcoming poster presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR virtual annual meeting.
Comment: Large MACD divergence into what seems like price consolidation. Expecting a big move within the next 3-5 days.

Comments

4.3 pm
Reply
maybe just a delay due to holiday... still c 3.50
Reply
Wow. Spot on it seems.
Reply
Making good progress!
Reply
Inverse H&S forming on 1 hr

Reply
jfs2152 jfs2152
@jfs2152, Invalidated!
Reply
@jfs2152, how much should i invest in this please help
Reply
We wait and see !!!! Good work still
Reply